tbuckley/cabot-search huggingface dataset:
MUC16 Regulates TSPYL5 for Lung Cancer Cell Growth and Chemoresistance by Suppressing p53
Authors: Imayavaramban Lakshmanan, Shereen Salfity, Parthasarathy Seshacharyulu, Satyanarayana Rachagani, Abigail Thomas, Srustidhar Das, Prabin D. Majhi, Rama Krishna Nimmakayala, Raghupathy Vengoji, Subodh M. Lele, Moorthy P. Ponnusamy, Surinder K. Batra, Apar Kishor Ganti
Journal: Clinical Cancer Research (2017)

Purpose: MUC16, a tumor biomarker and cell surface-associated mucin, is overexpressed in various cancers; however, its role in lung cancer pathogenesis is unknown. Here, we have explored the mechanistic role of MUC16 in lung cancer.Experimental Design: To identify the functional role of MUC16, stable knockdown was carried in lung cancer cells with two different shRNAs. Clinical significance of MUC16 was evaluated in lung cancer patient tissues using IHC. We have generated genetically engineered mouse model (KrasG12D; AdCre) to evaluate the preclinical significance of MUC16.Results: MUC16 was overexpressed (P = 0.03) in lung cancer as compared with normal tissues. MUC16 knockdown (KD) in lung cancer cell lines decreased the in vitro growth rate (P < 0.05), migration (P < 0.001), and in vivo tumor growth (P = 0.007), whereas overexpression of MUC16-carboxyl terminal (MUC16-Cter) resulted in increased growth rate (P < 0.001). Transcriptome analysis of MUC16 KD showed a downregulation (P = 0.005) of TSPYL5 gene, which encodes for a testis-specific Y-like protein. Rescue studies via overexpression of MUC16-Cter in MUC16 KD cells showed activation of signaling proteins, such as JAK2 (Y1007/1008), STAT3 (Y705), and glucocorticoid receptor (GR), which constitutes an important axis for the regulation of TSPYL5 for oncogenic process. Further, inhibition of STAT3 (Y705) led to decreased GR and TSPYL5, suggesting that MUC16 regulates TSPYL5 through the JAK2/STAT3/GR axis. Also, MUC16 overexpression induced cisplatin and gemcitabine resistance by downregulation of p53.Conclusions: Our findings indicate a significant role of MUC16 in tumorigenesis and metastasis of lung cancer cells possibly via regulation of TSPYL5 through the JAK2/STAT3/GR axis. Clin Cancer Res; 23(14); 3906-17. ©2017 AACR.
Driver Mutations and Prognosis in 502 Patients with Essential Thrombocythemia
Authors: Yoseph Elala, Terra L. Lasho, Naseema Gangat, Christy Finke, A Kamel Abou Hussein, Curtis A. Hanson, Rhett P. Ketterling, Animesh Pardanani, Ayalew Tefferi
Journal: Blood (2015)
Incidentaloma in the Right Iliac Fossa
Authors: Nitin Vashistha, Bharat Aggarwal, Dinesh Singhal
Journal: JAMA Surgery (2017)

A woman in her early 70s underwent laparoscopic right partial nephrectomy for oncocytoma. During workup, she was found to have an asymptomatic cystic lesion in right iliac fossa. What is your diagnosis?
Identification of the JAK/STAT Signaling Pathway as a Valid Therapeutic Target of T(8;21) Acute Myeloid Leukemia Using Combined Gene Expression and Promoter Occupancy Profiling.
Authors: Miao-Chia Lo, Luke F. Peterson, Ming Yan, Eun-Young Ahn, Hans B. Ommen, I-Ming Chen, Peter Hokland, Cheryl L. Willman, Dong-Er Zhang
Journal: Blood (2008)
Effect of availability of HIV self-testing on HIV testing frequency in gay and bisexual men at high risk of infection (FORTH): a waiting-list randomised controlled trial
Authors: Muhammad S Jamil, Garrett Prestage, Christopher K Fairley, Andrew E Grulich, Kirsty S Smith, Marcus Chen, Martin Holt, Anna M McNulty, Benjamin R Bavinton, Damian P Conway, Handan Wand, Phillip Keen, Jack Bradley, Johann Kolstee, Colin Batrouney, Darren Russell, Matthew Law, John M Kaldor, Rebecca J Guy
Journal: The Lancet HIV (2017)
Novel Patient Derived Multiple Myeloma Model Reflects Sensitivity Towards Anticancer Treatment in Multiple Myeloma Patients
Authors: Julia B. Schueler, Dagmar Wider, Kerstin Klingner, Gabrielle Melanie Siegers, Annette M May, Johannes M. Waldschmidt, Alexander Keller, Justus Duyster, Ralph M. Waesch, Monika Engelhardt
Journal: Blood (2015)
Evaluation of tumor- and stromal immune marker heterogeneity in non-small cell lung cancer
Authors: D. Casadevall Aguilar, L. Pijuan, S. Clave, A. Taus, A. Hernández, M. Lorenzo, S. Mojal, S. Menéndez, J. Albanell, M. Salido, E. Arriola
Journal: Annals of Oncology (2016)
Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 in Patients with Poor Prognosis Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS).
Authors: Francis J. Giles, Heidi Steinfeldt, William T. Bellamy, Paul Bycott, Yazdi Pithavala, Steven D. Reich, Alan F. List
Journal: Blood (2004)
Expression of Vascular Endothelial Growth Factor Receptors VEGFR-1 and VEGFR-2 Are Prognostic Factors in Normal Karyotype Acute Myeloid Leukemia (NK-AML)
Authors: Kellie M. Demock, Joseph Marinaro, Amanda Sobczyk, Laurie Ann Ford, Meir Wetzler, George Deeb, Lili Tian, Eunice S. Wang
Journal: Blood (2008)
Allogeneic Stem Cell Transplantation from Unrelated Donors after Reduced Intensity Conditioning in Patients with MDS/sAML. A Report from the Chronic Leukemia Working Party (CLWP) of the EBMT.
Authors: Nicolaus Kroeger, Ronald Brand, Rodrigo Martino, Philippe Guardiola, Anja van Biezen, Axel Zander, Dietger Niederwieser, Theo De Witte
Journal: Blood (2004)
Prmt5 Negatively Regulates Erythropoiesis By Multiple Mechanisms, Including Controlling DNA Methyltransferase 3A Protein Levels
Authors: Pierre-Jacques Hamard, Luisa Luciani, Fan Liu, Guoyan Cheng, Megan A. Hatlen, Olga A Guryanova, Xinyang Zhao, Ross L. Levine, Stephen D. Nimer
Journal: Blood (2015)
Pulmonary nodules in African migrants caused by chronic schistosomiasis
Authors: Federico Gobbi, Dora Buonfrate, Andrea Angheben, Anna Beltrame, Matteo Bassetti, Luca Bertolaccini, Giuseppe Bogina, Simone Caia, Silvia Duranti, Maria Gobbo, Valentina Marchese, Stefania Marocco, Maria Merelli, Geraldo Monteiro, Alberto Terzi, Zeno Bisoffi
Journal: The Lancet Infectious Diseases (2017)
HLA-Haploidentical Familial Donor Hematopoietic Cell Transplantation without Ex Vivo- T Cell Depletion after Reduced-Intensity Conditioning of Busulfan, Fludarabine, and Anti-Thymocyte Globulin: A Preliminary Report.
Authors: Kyoo-Hyung Lee, Seong-Jun Choi, Jung-Hee Lee, Ho-Jin Shin, Young-Shin Lee, Young-Ah Kang, Miee Seol, Seong-Gil Ryu, Je-Hwan Lee
Journal: Blood (2007)
FDA Approval Summary: TAS-102
Authors: Leigh Marcus, Steven J. Lemery, Sachia Khasar, Emily Wearne, Whitney S. Helms, Weishi Yuan, Kun He, Xianhua Cao, Jingyu Yu, Hong Zhao, Yaning Wang, Olen Stephens, Erika Englund, Rajiv Agarwal, Patricia Keegan, Richard Pazdur
Journal: Clinical Cancer Research (2017)

The FDA approved TAS-102 (Lonsurf; Taiho Oncology, Inc.) for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; an anti-VEGF biological therapy; and if RAS wild type, an anti-EGFR therapy. In an international, multicenter, double-blinded, placebo-controlled trial (TPU-TAS-102-301, herein referred to as RECOURSE), 800 patients with previously treated mCRC were randomly allocated (2:1) to receive either TAS-102 35 mg/m2 orally twice daily after meals on days 1 through 5 and 8 through 12 of each 28-day cycle (n = 534) or matching placebo (n = 266). The trial demonstrated a statistically significant improvement in overall survival for those randomized to receive TAS-102, with a median survival of 7.1 months in the TAS-102 arm [confidence interval (CI), 6.5-7.8] and 5.3 months in the placebo arm [CI, 4.6-6.0; hazard ratio (HR), 0.68; 95% CI, 0.58-0.81; P < 0.001, stratified log-rank test]. The trial also demonstrated a statistically significant prolongation of progression-free survival (HR, 0.47; 95% CI, 0.40-0.55; P < 0.001). The most common adverse reactions, in order of decreasing frequency, observed in the patients who received TAS-102 were anemia, neutropenia, asthenia/fatigue, nausea, thrombocytopenia, decreased appetite, diarrhea, vomiting, abdominal pain, and pyrexia. Adverse events led to discontinuation of TAS-102 in 3.6% of patients, and 13.7% required a dose reduction. The most common adverse reactions leading to dose reduction were neutropenia, anemia, febrile neutropenia, fatigue, and diarrhea. Clin Cancer Res; 23(12); 2924-7. ©2017 AACR.
Comment on Methodology and Interpretation of Results: Reply
Authors: Alain F. Pelfrene
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article Comment on Methodology and Interpretation of Results: Reply Get access Alain F. Pelfrene, M.D., Ph.D. Alain F. Pelfrene, M.D., Ph.D. Director Director, Product Safety Assessment Centre de Recherche Pharmaceutique Sophia Antipotis, 06560 Valbonne, France Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 59, Issue 5, November 1977, Pages 1341–1342, https://doi.org/10.1093/jnci/59.5.1341-a Published: 01 November 1977
Phase 1 study of MEDI0562, a humanized OX40 agonist monoclonal antibody (mAb), in adult patients (pts) with advanced solid tumors
Authors: B.S. Glisson, R. Leidner, R.L. Ferris, J. Powderly, N. Rizvi, J.D. Norton, J. Burton, M.C. Lanasa, S.P. Patel
Journal: Annals of Oncology (2016)
The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma
Authors: Shmuel Yaccoby, Joshua Epstein, Sarah K. Johnson, Pingping Qu, Frits van Rhee, Yogesh Jethava, Caleb K. Stein, Emily Hansen, Alan Mitchell, Maurizio Zangari, Christoph Heuck, Rashid Z Khan, Xenofon Papanikolaou, Faith E Davies, Antje Hoering, John Crowley, Niels Weinhold, Bart Barlogie, Gareth J Morgan
Journal: Blood (2015)
Evaluation of MET gene status in malignant mesothelioma by fluorescent in situ hybridization
Authors: A. Vigani, S. Salvi, S. Varesano, S. Boccardo, P. Ferro, P.A. Canessa, M.C. Franceschini, P. Dessanti, J.L. Ravetti, F. Fedeli, M.P. Pistillo, S. Roncella
Journal: Annals of Oncology (2016)
CCR5 Chemokine Receptor Expression Can Promote Disease Progression in Non-Hodgkin’s Lymphoma.
Authors: Grzegorz Mazur, Ilona Kryczek, Tomasz Wrobel, Dorota Dlubek, Aleksandra Klimczak, Emilia Jaskula, Michal Jelen, Andrzej Lange, Kazimierz Kuliczkowski
Journal: Blood (2006)
Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as predictive biomarkers of pathologic complete response (pCR) in neoadjuvant breast cancer: an Irish Clinical Oncology Group study (ICORG 16-20)
Authors: S. Rafee, D.J. McHugh, M. Greally, O. Ayodele, N. Keegan, M. Lim, A. Hassan, D. O'Mahony, B. Hennessy, C. Kelly, J. Kennedy, J. Walshe, M. O'Connor, G. Leonard, V. Murphy, V. Livingstone, M. Corrigan, S. O'Reilly
Journal: Annals of Oncology (2016)
Clinical and Haematologic Features of 300 Patients Affected by Hereditary Spherocytosis as a Function of the Type of the Membrane Protein Defect.
Authors: Wilma Barcellini, Mariagabriella Mariani, Cristina Vercellati, Anna P. Marcello, Elisa Fermo, Paola Pedotti, Carla Boschetti, Alberto Zanella
Journal: Blood (2007)
MPTH-16. EXPRESSION OF METABOLIC ENZYMES AS PREDICTORS OF PROGNOSIS IN PATIENTS WITH AGGRESSIVE PRIMARY BRAIN CANCERS
Authors: Mohammed Shaik, Mary Noel, Kenneth Schwartz, Karl Olson, Howard Chang
Journal: Neuro-Oncology (2016)

Aggressive primary brain cancers like glioblastoma multiforme (GBM) are metabolically active tumors. We hypothesis that abnormal expression of metabolic enzymes may reflect the tumors increased metabolism and be useful in predicting survival. 60 patients (45 with GBM, 11 with anaplastic gliomas and 4 with gliosarcoma) were evaluated using Immunohistochemistry (IHC) to measure the relative concentrations of the glycolytic enzyme hexokinase-II (HK2) a known predictor of poor prognosis and several ketolytic enzymes including cytosolic type 2(R)-hydroxybutyrate dehydrogenase (BDH-2). The immunoreactivities were graded based on the percentage of positive cells: Positive (≥20%), Negative (< 20%). Survival was calculated using Kaplan Meier (KM) and an age adjusted hazard ratio (aHR) for death was obtained using Cox proportional analysis for enzyme expression. Significance p ≤ 0.05. Demographics for 60 patients; 19 female and 41 males, median age 62 years, and median survival for all the patients 5.9 months. Univariate analysis showed positive HK2 and negative BDH-2 expression had decreased survival with HR of 1.8 (p=0.06) and 2.6 (p=0.01) respectively. In a multivariate analysis after adjusting to age, histology and other enzyme expression, positive HK2 and negative BDH-2 expression were statistically associated with decreased survival (aHR of 11.3 p= 0.001 and 32.6, p=0.0004), respectively. The group with favorable prognosis (negative HK2 or positive BDH-2 expression) (n=36) had a median survival of 9.7 months (95% CI 4.2 -13.5) whereas the group with non-favorable prognosis (n=24) had a median survival of 3.1months (95% CI 1.8 – 5.8). IHC helps to confirm the poor prognosis associated with positive HK-2 and suggests that negative IHC expression of BDH-2 may be a new indicator of poor prognosis for patients with aggressive primary brain cancers.
Molecular profiling in advanced non-small-cell lung cancer: preliminary data of the Italian observational prospective study
Authors: E. Gobbini, V. Grecorc, D. Galetta, F. Riccardi, M. Tiseo, V. Scotti, A. Ceribelli, L. Buffoni, E. Maiello, A. Delmonte, T. Franchina, M.R. Migliorino, D. Cortinovis, S. Pisconti, M. Di Maio, P. Graziano, E. Bria, G. Rossi, A. Rossi, S. Novello
Journal: Annals of Oncology (2016)
CSIG-12. EXAMINATION OF THE KYNURENINE PATHWAY AND ARYL HYDROCARBON RECEPTOR IN LOW- AND HIGH-GRADE MENINGIOMAS
Authors: Sharon K. Michelhaugh, Anthony R. Guastella, Sam Kiousis, Sandeep Mittal
Journal: Neuro-Oncology (2016)

Surgical resection of benign (grade I) meningioma (MEN) tumors is typically an effective treatment strategy and yields a good prognosis, treatment options for recurrent, aggressive, or unresectable MENs are highly limited leading to very poor prognosis. The kynurenine (KYN) pathway of tryptophan (TRP) metabolism and its downstream target, the aryl hydrocarbon receptor (AHR), may provide actionable drug targets for these patient populations. Tissue microarrays (TMA) including all three histologic grades (n=16 per grade) were studied with immunohistochemistry (IHC) to detect indoleamine 2,3-dioxygenase 1 (IDO1), indoleamine 2,3-dioxygenase-2 (IDO2), tryptophan 2,3-dioxygenase (TDO2), AHR, and the large amino acid transporter 1 (LAT1), as well as the diagnostic epithelial membrane antigen (EMA) and vimentin. Stained slides were scored using the Densitoquant application in TMA Module v.2 software (3DHISTECH). Primary cultures of patient-derived MEN cell lines were treated with IDO1, IDO2 or TDO2 inhibitors, or an AHR antagonist and cell proliferation was assessed. All meningioma specimens were positive for EMA, vimentin, and LAT1. IDO1 and IDO2 were detected at low levels in grade I and higher levels in grades II and III, while staining for TDO2 was at high levels in all three grades. AHR staining was positive in ~50% of grade I and >80% of grade II and III tumor sections. Inhibition of TDO2 and antagonism of AHR significantly decreased cell proliferation in MEN cells in vitro. TDO2 and AHR of the KYN pathway of TRP metabolism may prove to be valuable targets for the development of new therapeutic agents for the treatment of poor prognosis MENs.
Corrigendum to “Sustained localized presentation of RNA interfering molecules from in situ forming hydrogels to guide stem cell osteogenic differentiation” [Biomaterials 35/24 (2014) 6278–6286]
Authors: Minh K. Nguyen, Oju Jeon, Melissa D. Krebs, Daniel Schapira, Eben Alsberg
Journal: Biomaterials (2017)
blockade overcomes primary and acquired resistance to anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer (mCRC)
Authors: G. Martini, V. Belli, P.P. Vitiello, T. Troiani, C. Cardone, S. Napolitano, V. Desiderio, V. Sforza, M.L. Ferrara, G. Papaccio, L. Mele, G. Liguori, G. Botti, R. Franco, F. Morgillo, F. Ciardiello, E. Martinelli
Journal: Annals of Oncology (2016)
Efficacy of cabazitaxel, abiraterone, enzalutamide and docetaxel sequence in men with metastatic castration-resistant prostate cancer (mCRPC) in real life practice: The multinational, retrospective, observational CATS study
Authors: A. Angelergues, A.J. Birtle, A.C. Hardy-Bessard, O. Caffo, S.L.e. Moulec, M. Krainer, A. Guillot, A. Hasbini, G. Daugaard, S. Chowdhury, D. Spaeth, P. Beuzeboc, J.-C. Eymard, A. Flechon, J. Alexandre, F. Priou, N. Delanoy, N. El Awadly, E. Braychenko, S. Oudard
Journal: Annals of Oncology (2016)
TMIC-12. TMZ RESULTS IN PRIMING OF HOST IMMUNITY AND CHANGES IN GBM TUMOR PDL-1 EXPRESSION IN A DOSE DEPENDENT FASHION THAT CAN BE LEVERAGED FOR COMBINATION WITH IMMUNE CHECKPOINT BLOCKADE
Authors: Aida Karachi, Hassan Azari, Catherine Flores, Changlin Yang, Farhad Dastmalchi, Duane Mitchell, Maryam Rahman
Journal: Neuro-Oncology (2016)

Glioblastoma is characterized by treatment resistance resulting in aggressive growth. Due to limited efficacy of current treatments, novel strategies are under investigation. In this study, we hypothesised that dose modified TMZ improves GBM response to immune check point blockade by priming host immunity and changing tumor microenvironment. Murine glioma cell lines were treated with TMZ and checked for PD-1, PDL-1. mice were injected with different doses of TMZ to evaluate PD-1, PDL-1 in lymphocytes at different time points post TMZ. mice recieved OT- 1 splenocytes pre and post TMZ to determine effects of TMZ on antigen specific T cell recovery. GL-261 and GL-261 overexpressing MGMT (GL-MGMT) were implanted intracerebrally to mice and treated with PD-1 blockade and TMZ for survival study. PDL-1 was increased in murine glioma cells with TMZ in a dose dependent fashion. Although TMZ induced lymphopenia, this was associated with an increase in PD-1 and decrease in TIM3 in lymphocytes at 1 week post treatment indicative of T cell activation. Antigen specific T cells (OT-1) expanded more in the setting of TMZ treatment and peaked at 2 weeks post-treatment. GL-261 and GL-MGMT tumor bearing animals treated with PD-1 blockade showed moderate extension in survival. GL-MGMT tumors did not respond to TMZ, whereas GL-261 tumors treated with TMZ survived longer. GL-261 tumors treated with combination of PD-1 blockade and TMZ showed extended survival. However, GL-MGMT tumors had reduced survival when TMZ was combined with PD-1 inhibition. TMZ induced higher expression of PD-1 in T cells and PDL-1 in GBM tumor cells. Antigen specific T cells expand in the setting of TMZ induced lymphopenia. PD-1 blockade increases survival of tumor bearing animals. However, combining this treatment with TMZ results in rapid tumor growth and animal death in MGMT overexpressing tumors. Further studies are necessary to investigate this phenomenon.
Integrated safety summary (ISS) for trifluridine/tipiracil (TAS-102)
Authors: A. Falcone, A. Ohtsu, E. Van Cutsem, R. Mayer, M. Buscaglia, J.C. Bendell, S. Kopetz, M. Wahba, P. Bebeau, T. Yoshino
Journal: Annals of Oncology (2016)
THE INFLUENCE OF PREVIOUS INJURY HISTORY ON HEALTH AND FITNESS OUTCOMES IN JUNIOR HIGH SCHOOL STUDENTS
Authors: Carla van den Berg, Patricia K Doyle-Baker, Alberto Nettel-Aguirre, Sarah Richmond, Carolyn Emery
Journal: British Journal of Sports Medicine (2017)

Background Children and youth who sustain a sport and recreational (S&amp;R) injury may be at greater risk of attributing long-term unhealthy body composition and low physical fitness. Objective To assess the potential influence of previous S&amp;R injury on body composition, cardiorespiratory fitness, musculoskeletal strength, and dynamic balance in junior high school students. Design Cross-sectional. Setting Junior high schools in Calgary, Alberta, Canada. Participants Students aged 11–16 years (n=1,039; 584 males and 455 females) from six junior high schools. Assessment of Risk Factors Participants reported information on demographics, sport participation over the previous year, and S&amp;R injuries sustained in the previous 12 months via a questionnaire. Main Outcome Measurements Physical fitness measures included predicted VO 2 max from a 20-m shuttle run to assess cardiorespiratory fitness, vertical jump to assess lower body musculoskeletal fitness, and the Y-balance and unipedal eyes closed balance tests to assess dynamic balance. Health outcome measures to assess body composition included waist circumference, and body mass index (BMI) calculated from height and weight measures. Statistical analyses (adjusting for age, sex, and mean weekly hours of sport participation) to assess the association between previous S&amp;R injury (yes/no) and each outcome included multivariable logistic regression for body composition measures and multivariable linear regression for physical fitness measures. Results One hundred eighty-eight (18.1%) students reported sustaining a S&amp;R injury in the previous year. Previously injured participants had significantly higher BMI (OR=1.82, 99% CI 1.07–3.11) compared to uninjured participants. Exploratory analysis results suggest a more in-depth look at the association between number of previous injuries and body composition. Conclusions Participants with a history of injury demonstrated unhealthier body composition compared to uninjured participants. Body composition should be considered in future injury prevention research in youth.
SURG-08. AWAKE-AWAKE-AWAKE CRANIOTOMIES IN GLIOMA SURGERY
Authors: Stephanie Schipmann, Isabelle Müller, Eric J. Suero, Matthias Maas, Michael Schwake, Christian Ewelt, Walter Stummer
Journal: Neuro-Oncology (2016)

For over 70 years, awake craniotomies have been part of the treatment of gliomas located in so called “eloquent regions”. The patients’ compliance plays an important role in the success of each surgery. Finding the optimal balance between dosage and type of sedative, analgesic and anxiolytic drugs and keeping the patient clinically and neurologically assessable remains challenging. Different techniques are applied in neurooncology centres; “Asleep-Awake-Asleep” and “Awake-Awake-Awake” are both techniques which have been applied in the Department of Neurosurgery, University Hospital of Muenster. Since the year of 2013, we performed solely “Awake-Awake-Awake” surgeries using the a2-receptor agonist dexmedetomidine as sole anaesthetic drug. The aim of this study was to compare both techniques and evaluate the clinical use of dexmedetomidine in the setting of awake-craniotomies for glioma surgery. We retrospectively analyzed patients that were operated in the Department of Neurosurgery, University Hospital of Muenster either under “Sleep-Awake-Sleep” or under “Awake-Awake-Awake” conditions. We evaluated the electronical medical record from each patient and the digitalized anesthetic protocols. Adverse events, as well as applied drugs with doses and frequency of usage were recorded. Compliance was evaluated according to the surgeons’ perception. Two-hundred twenty-four (n=224) awake surgeries were performed in the period from October 2009 till September 2015. In the “Awake-Awake-Awake” group (n=78) less opiates, less vasoactive and antihypertensive drugs were used in comparison to the “Sleep-Awake-Sleep” group (n=146). In addition, compliance was much higher rated in the “awake-awake-awake” group. Dexmedetomidine provides excellent setting for fully awake surgeries. Our experience shows that using dexmedetomidine as sole anaesthetic drug during awake craniotomies sedates moderately, acts anxiolytic and after ceasing infusion enables quick and reliable clinical neurological assessment of patients.